Do Not Initiate Finerenone at eGFR 18 mL/min/1.73 m²
Finerenone should not be started in a patient with an eGFR of 18 mL/min/1.73 m² as this falls below the established initiation threshold of ≥25 mL/min/1.73 m² 1, 2.
Initiation Threshold
The 2026 AHA/ACC/ADA/ASN guideline explicitly states that finerenone has an eGFR initiation threshold of ≥25 mL/min/1.73 m² 1. The ASN Kidney Health Guidance reinforces this, specifying that finerenone should be stopped when eGFR falls below 15 mL/min/1.73 m² 2. With an eGFR of 18 mL/min/1.73 m², this patient falls in the narrow window where continuation might be considered if already on therapy, but initiation is contraindicated.
Key Distinction: Continuation vs. Initiation
There is critical nuance here that affects clinical decision-making:
Continuation below threshold: Major clinical trials allowed finerenone to be continued after eGFR dropped below the 25 mL/min/1.73 m² initiation threshold, with ongoing benefit and no apparent increased adverse effects 1
New initiation: However, these benefits apply to patients already established on therapy, not to new starts at such low eGFR levels. The FIDELITY meta-analysis showed directionally similar cardiovascular benefit in CKD G4 (eGFR 15-29 mL/min/1.73 m²), but this was nonsignificant and requires further investigation 1
Safety Concerns at Low eGFR
Hyperkalemia risk increases substantially at lower eGFR levels 1, 2. The FIDELITY analysis specifically noted that hyperkalemia was more frequent in patients with CKD G4 treated with finerenone 1. At eGFR 18, the patient has:
- Severely reduced potassium excretion capacity
- Likely already on RAS inhibitors (which further increase hyperkalemia risk)
- Limited ability to tolerate additional potassium-elevating medications
Clinical Algorithm
If this patient has compelling indications for mineralocorticoid receptor antagonism:
Optimize existing kidney-protective therapies first: Ensure maximal tolerated doses of RAS inhibitors and SGLT2 inhibitors (which can be initiated at eGFR ≥20 mL/min/1.73 m²) 1, 2
Monitor trajectory: If eGFR improves above 25 mL/min/1.73 m² with optimization of other therapies, finerenone initiation could be reconsidered
Consider alternative MRA: If mineralocorticoid receptor antagonism is absolutely necessary, this would require extremely careful monitoring and is generally not recommended at this eGFR level
Prepare for renal replacement therapy: At eGFR 18, focus should shift toward preparing for dialysis or transplant evaluation
Bottom Line
The evidence-based initiation threshold exists for patient safety. Starting finerenone at eGFR 18 mL/min/1.73 m² contradicts current guideline recommendations and exposes the patient to unacceptable hyperkalemia risk without established benefit at this level of kidney function 1, 2.